Literature DB >> 33238741

Risk stratification in cardiomyopathy.

Gianfranco Sinagra1, Cosimo Carriere1, Francesco Clemenza2, Chiara Minà2, Francesco Bandera3, Denise Zaffalon1, Paola Gugliandolo3, Marco Merlo1, Marco Guazzi3, Piergiuseppe Agostoni3,4.   

Abstract

Prognostic stratification of cardiomyopathies represents a cornerstone for the appropriate management of patients and is focused mainly on arrhythmic events and heart failure. Cardiopulmonary exercise testing provides additional prognostic information, particularly in the setting of heart failure. Cardiopulmonary exercise testing data, integrated in scores such as the Metabolism Exercise Cardiac Kidney Index score have been shown to improve the risk stratification of these patients. Cardiopulmonary exercise testing has been analysed as a potential supplier of prognostic parameters in the context of hypertrophic cardiomyopathy, for which it has been shown that a reduced oxygen consumption peak, an increased ventilation/carbon dioxide production slope and chronotropic incompetence correlate with a worse prognosis. To a lesser extent, in dilated cardiomyopathy, it has been shown that the percentage of oxygen consumption peak, not the pure value, and the ventilation/carbon dioxide production slope are associated with a greater cardiovascular risk. Few data are available about other cardiomyopathies (arrhythmogenic and restrictive). Cardiomyopathy patients should be early and routinely referred to heart failure advanced centres in order to perform a comprehensive risk stratification which should include a cardiopulmonary exercise test, with variables and cut-offs shown to improve their risk stratification.

Entities:  

Keywords:  CPET; Cardiomyopathy; MECKY score; exercise; prognosis; risk stratification

Mesh:

Substances:

Year:  2020        PMID: 33238741      PMCID: PMC7691630          DOI: 10.1177/2047487320961898

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  27 in total

1.  Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.

Authors:  Damiano Magri; Piergiuseppe Agostoni; Gianfranco Sinagra; Federica Re; Michele Correale; Giuseppe Limongelli; Elisabetta Zachara; Vittoria Mastromarino; Caterina Santolamazza; Matteo Casenghi; Giuseppe Pacileo; Fabio Valente; Marco Morosin; Beatrice Musumeci; Erika Pagannone; Antonello Maruotti; Massimo Uguccioni; Massimo Volpe; Camillo Autore
Journal:  Int J Cardiol       Date:  2018-08-04       Impact factor: 4.164

Review 2.  Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Eli Muchtar; Lori A Blauwet; Morie A Gertz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

3.  Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2018-05-23       Impact factor: 12.035

Review 4.  Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Jose F Huizar; Kenneth A Ellenbogen; Alex Y Tan; Karoly Kaszala
Journal:  J Am Coll Cardiol       Date:  2019-05-14       Impact factor: 24.094

5.  Right Ventricular Contractile Reserve and Pulmonary Circulation Uncoupling During Exercise Challenge in Heart Failure: Pathophysiology and Clinical Phenotypes.

Authors:  Marco Guazzi; Simona Villani; Greta Generati; Ottavia Eleonora Ferraro; Marta Pellegrino; Eleonora Alfonzetti; Valentina Labate; Maddalena Gaeta; Tadafumi Sugimoto; Francesco Bandera
Journal:  JACC Heart Fail       Date:  2016-05-11       Impact factor: 12.035

Review 6.  Cardiopulmonary Exercise Test in Hypertrophic Cardiomyopathy.

Authors:  Damiano Magrì; Caterina Santolamazza
Journal:  Ann Am Thorac Soc       Date:  2017-07

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

8.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

9.  Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.

Authors:  Petar M Seferović; Marija Polovina; Johann Bauersachs; Michael Arad; Tuvia Ben Gal; Lars H Lund; Stephan B Felix; Eloisa Arbustini; Alida L P Caforio; Dimitrios Farmakis; Gerasimos S Filippatos; Elias Gialafos; Vladimir Kanjuh; Gordana Krljanac; Giuseppe Limongelli; Aleš Linhart; Alexander R Lyon; Ružica Maksimović; Davor Miličić; Ivan Milinković; Michel Noutsias; Ali Oto; Öztekin Oto; Siniša U Pavlović; Massimo F Piepoli; Arsen D Ristić; Giuseppe M C Rosano; Hubert Seggewiss; Milika Ašanin; Jelena P Seferović; Frank Ruschitzka; Jelena Čelutkiene; Tiny Jaarsma; Christian Mueller; Brenda Moura; Loreena Hill; Maurizio Volterrani; Yuri Lopatin; Marco Metra; Johannes Backs; Wilfried Mullens; Ovidiu Chioncel; Rudolf A de Boer; Stefan Anker; Claudio Rapezzi; Andrew J S Coats; Carsten Tschöpe
Journal:  Eur J Heart Fail       Date:  2019-04-16       Impact factor: 17.349

10.  Characterization of Cardiopulmonary Exercise Testing Variables in Patients with Endomyocardial Fibrosis after Endocardial Resection.

Authors:  Ana Luiza C Sayegh; Marcelo R Dos Santos; Patricia de Oliveira; Fábio Fernandes; Eduardo Rondon; Francis R de Souza; Vera M C Salemi; Maria Janieire de N N Alves; Charles Mady
Journal:  Arq Bras Cardiol       Date:  2017-12       Impact factor: 2.000

View more
  2 in total

Review 1.  Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives.

Authors:  Mattia Zampieri; Martina Berteotti; Cecilia Ferrantini; Luigi Tassetti; Martina Gabriele; Benedetta Tomberli; Gabriele Castelli; Francesco Cappelli; Pierluigi Stefàno; Niccolò Marchionni; Raffaele Coppini; Iacopo Olivotto
Journal:  Curr Heart Fail Rep       Date:  2021-06-20

Review 2.  The Role of Exercise-Induced Molecular Processes and Vitamin D in Improving Cardiorespiratory Fitness and Cardiac Rehabilitation in Patients With Heart Failure.

Authors:  Aneta Aleksova; Milijana Janjusevic; Giulia Gagno; Alessandro Pierri; Laura Padoan; Alessandra Lucia Fluca; Cosimo Carriere; Antonio Paolo Beltrami; Gianfranco Sinagra
Journal:  Front Physiol       Date:  2022-01-11       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.